𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome

✍ Scribed by Youngtae Hong; Seung Shin Yu; Jong-Mook Kim; Karim Lee; Young Soon Na; Chester B. Whitley; Yoshikazu Sugimoto; Sunyoung Kim

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
216 KB
Volume
5
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

As an alternative method to the conventional therapies for Hunter's syndrome, which is a lethal lysosomal storage disorder, we have developed gene delivery vehicles using a series of retroviral vectors. The objective of this study was to develop a safe and efficient retroviral vector and to optimize conditions for efficient transduction of human bone marrow CD34+ stem cells using our vector.

Methods

We constructed three types of MLV‐based retroviral vectors expressing iduronate‐2‐sulfatase (IDS) which is deficient in patients suffering from Hunter's syndrome: MIN‐IDS and MIM‐IDS, which express IDS along with bacterial neo and human MDR genes, respectively, and MT‐IDS lacking any selectable marker. Respective producer lines were derived from the packaging line, PG13, and compared for viral titer and levels of gene expression. After comparing, the retroviral vector, MT‐IDS, was used to transduce human bone marrow CD34+ stem cells on fibronectin under various MOIs.

Results

In comparison, MT‐IDS not only produced the highest viral titer (close to 10^7^ cfu/ml), but also showed the highest level of gene expression in various transduction assays and RNA analysis. When 1.5 × 10^5^ human CD34+ bone marrow cells were transduced with MT‐IDS under the most optimal MOIs, about 80% of total colony forming units were shown to contain the IDS cDNA.

Conclusions

Minimum‐sized retroviral vector that contains no selective marker as well as a viral coding sequences could drive a high level of gene expression, be produced efficiently from the producer line, and enter hematopoietic cells at a high frequency. Our data suggest the great potential for using MT‐based vector(s) in a gene therapy trial for Hunter's syndrome utilizing human CD34+ stem cells as target cells. Copyright © 2002 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Endostatin- and interleukin-2-expressing
Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma
✍ Flávia Gomes de Góes Rocha; Fernanda B. Calvo; Karen C. Chaves; Jean P. S. Peron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 556 KB

## Abstract ## Background Metastatic renal cell carcinoma (mRCC) is one of the most treatment‐resistant malignancies. Despite all new therapeutic advances, almost all patients develop resistance to treatment and cure is rarely seen. In the present study, we evaluated the antitumor effect of a bici

Entrapment of retroviral vector producer
Entrapment of retroviral vector producer cells in three-dimensional alginate scaffolds for potential use in cancer gene therapy
✍ Mona Dvir-Ginzberg; Alexander Konson; Smadar Cohen; Riad Agbaria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB 👁 1 views

## Abstract Abstract: We explored the possibility of entrapping retroviral vector producing cells (VPC) within porous 3D matrix to induce a local and sustained release of viral particles to the malignant milieu. PA317/STK, which constantly shed reroviral vectors, was used to transduce cancer cells

Effect of medium sugar source on the pro
Effect of medium sugar source on the production of retroviral vectors for gene therapy
✍ A.S. Coroadinha; J. Ribeiro; A. Roldão; P.E. Cruz; P.M. Alves; O.-W. Merten; M.J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

## Abstract The production of gene therapy retroviral vectors presents many difficulties, mainly due to vector instability and low cell productivities hampering the attainment of high titers of infectious viral vectors. The objective of this work is to increase the production titers of retroviral v

Purification of a cystic fibrosis plasmi
Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography
✍ M. M. Diogo; J. A. Queiroz; G. A. Monteiro; S. A. M. Martins; G. N. M. Ferreira; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 2 views

The success and validity of gene therapy and DNA vaccination in in vivo experiments and human clinical trials depend on the ability to produce large amounts of plasmid DNA according to defined specifications. A new method is described for the purification of a cystic fibrosis plasmid vector (pCF1-CF

Development of an in vitro cell culture
Development of an in vitro cell culture assay system for measuring the activation of a neighbouring gene by the retroviral vector
✍ Youngtae Hong; Seung Shin Yu; Nam-Kyung Yoon; Sung June Kang; Jun-Tae Lee; Sujeo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract ## Background The use of retroviral vectors has shown an actual clinical benefit in a few inherited diseases. However, the occurrence of cases of leukemia after the X‐SCID gene therapy trial raised concerns about the safety of insertional mutagenesis inherent to the biology of the retr